- Efforts to manipulate growth factors including those being undertaken by Athira and Synaptogenix are unlikely to be successful because the pathway through which growth factors work is inhibited by nitration.
- Anti-amyloid treatments such as those being undertaken by Biogen and Eisai, Eli Lilly, and Alzheon appear to only modestly slow down the progression of the disease in APOE4 carriers.
- Aricept and Cassava Sciences' simufilam may accelerate the decomposition of the nitro-oxidant peroxynitrite, which may partially explain why they lead to improvements in cognition that are maintained for a while.
- Drugs and natural products that scavenge peroxynitrite, including Anavex's blarcamesine, Cyclo Therapeutics Trappsol Cyclo, and panax ginseng may lead to improvements in cognition that are sustained for a long time.
For further details see:
Pathways Impacting Alzheimer's Disease Drug Development